Search results for "TUMORS"

showing 10 items of 1138 documents

Molecular chaperones in tumors of salivary glands.

2020

The salivary glands are key components of the mouth and play a central role in its physiology. Their importance may be appreciated considering their number, occurrence in pairs, and distribution in the mouth: two parotids, two submandibular, two sublingual, and many other small ones scattered throughout the mouth. They produce saliva, without which ingestion of non-liquid nutrients and speech would be practically impossible. Nevertheless, the physiology and pathology of salivary glands are poorly understood. For instance, tumors of salivary glands occur, and their incidence is on the rise, but their etiology and pathogenesis are virtually unknown, although some risk factors have been identi…

0301 basic medicineSalivaHistologyPhysiologyDifferential diagnosiBiologyBioinformaticsmedicine.disease_causePathogenesis03 medical and health sciencesstomatognathic systemmedicineHSPAnimalsHumansEndoplasmic Reticulum Chaperone BiPTumorsSalivary glandTumorigenesiChaperoning system030102 biochemistry & molecular biologySalivary glandCell BiologyGeneral MedicineSalivary Gland Neoplasms030104 developmental biologymedicine.anatomical_structureCell Transformation NeoplasticChaperone (protein)Etiologybiology.proteinMolecular chaperoneBiomarker (medicine)Disease SusceptibilityDifferential diagnosisCarcinogenesisMolecular ChaperonesJournal of molecular histology
researchProduct

Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal c…

2019

Abstract Human (gamma delta) γδ T cells are unconventional innate-like lymphocytes displaying a broad array of anti-tumor activities with promising perspectives in cancer immunotherapy. In this context, Vδ2pos T cells represent the preferential target of several immunotherapy protocols against solid tumors. However, the impact of both aging and chemotherapy (CHT) on Vδ2pos T cells is still unknown. The present study evaluates with multi-parametric flow cytometry the frequencies, terminal differentiation, senescence and effector-functions of peripheral blood and tumor infiltrating Vδ2pos T cells purified from liver metastases (CLM) of patients affected by colorectal cancer (CRC) compared to …

0301 basic medicineSenescenceCancer ResearchColorectal cancermedicine.medical_treatmentImmunologyShort ReportContext (language use)Antineoplastic AgentsCD16lcsh:RC254-282γδ T cellsFlow cytometryImmunophenotyping03 medical and health sciences0302 clinical medicineCancer immunotherapyT-Lymphocyte SubsetsCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsmedicineImmunology and AllergyChemotherapyHumansCellular SenescenceCancerPharmacologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCD28Receptors Antigen T-Cell gamma-deltaImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistry030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchMolecular MedicineImmune-senescence/AgingbusinessColorectal NeoplasmsBiomarkersJournal for Immunotherapy of Cancer
researchProduct

Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential

2018

Abstract: Introduction: Pancreatic neuroendocrine tumors (pNETs) represent a small part of pancreatic neoplasms, and the knowledge about their indolent clinical course remains a subject of investigation. They occur sporadically or as part of familial cancer syndromes and are classified by WHO in 3 categories. There is ongoing research to understand their molecular profiling and leading mutations.Areas covered: The aim of this review is to clarify the overall aspects of tumorigenesis, to expose the latest developments in understanding the course of the disease and the possible therapeutic implications of these. The review also discusses functional and non-functional pNETs and associated inhe…

0301 basic medicineSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical Decision-MakingAntineoplastic AgentsDiseaseNeuroendocrine tumorsBioinformaticsTargeted therapy03 medical and health sciences0302 clinical medicinePredictive Value of TestsFunctional tumorBiomarkers TumormedicineHumansProfiling (information science)Molecular Targeted Therapyneurondocrine tumorPrecision MedicineTherapeutic strategymolecular pathwayHepatologybusiness.industryGene Expression ProfilingGastroenterologyClinical coursehereditary syndrometargeted therapymedicine.diseaseGene Expression Regulation NeoplasticPancreatic NeoplasmsNeuroendocrine Tumors030104 developmental biology030220 oncology & carcinogenesispancreatic tumorFamilial CancerHuman medicinebusinessSignal TransductionExpert review of gastroenterology & hepatology
researchProduct

Helicobacter pylori and Epstein–Barr Virus Infection in Gastric Diseases: Correlation with IL-10 and IL1RN Polymorphism

2019

Introduction. Helicobacter pylori and Epstein–Barr virus (EBV) infection have recently been shown to be associated with gastric diseases. Polymorphisms in genes encoding cytokines such as interleukin 10 (IL-10) and interleukin 1 Receptor (IL-1RN) influence cytokine secretion levels and appear to contribute to the risk of developing gastroduodenal diseases. To our knowledge, this is the first preliminary study to address the association of coinfection with H. pylori and EBV and their correlation with genetic predisposition in the development of gastric diseases. Methods. Gastric biopsy samples of 96 patients with different gastric diseases were used. Results. Our results showed that the rate…

0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia ClinicaArticle Subjectpolymorphism gastric cancer IL-10Chronic gastritislcsh:RC254-28203 medical and health sciences0302 clinical medicineEBVHelicobactermedicineCagAEpstein–Barr virus infectionbiologybusiness.industryMALT lymphomaHelicobacter pylorimedicine.diseasebiology.organism_classificationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseases030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyCoinfectionCytokine secretionGastritismedicine.symptombusinessResearch ArticleJournal of Oncology
researchProduct

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a rando…

2019

PMC6682346; Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. An earlier randomized Phase IIa trial in predominantly sorafenib-naive hepatocellular carcinoma (HCC) demonstrated an overall survival (OS) benefit. This randomized, open-label Phase IIb trial investigated whether Pexa-Vec plus Best Supportive Care (BSC) improved OS over BSC alone in HCC patients who failed sorafenib therapy (TRAVERSE). 129 patients were randomly assigned 2:1 to Pexa-Vec plus BSC vs. BSC alone. Pexa-Vec was given as a single intravenous (IV) infusion fol…

0301 basic medicineSorafenibOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyHepatocellular carcinomamedicine.medical_treatmentImmunologyPexastimogene-devacirepvecAucunSciences du Vivant [q-bio]/Médecine humaine et pathologielcsh:RC254-28203 medical and health scienceschemistry.chemical_compound0302 clinical medicineAntigenInternal medicinemedicineClinical endpointImmunology and AllergyHepatocellular carcinoma; oncolytic immunotherapy; oncolytic vaccinia; Pexa-Vec; sorafeniboncolytic vacciniaOriginal Researchbusiness.industryImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOncolytic virus030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisHepatocellular carcinomaPexa-Veconcolytic immunotherapysorafenibVacciniabusinesslcsh:RC581-607[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS

2017

Background and aims Nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) recognize obesity and insulin resistance (IR) as common pathogenic background. We assessed 1) whether PCOS is a risk factor for steatosis, and 2) the impact, in PCOS patients, of IR and hyperandrogenism on steatosis and fibrosis. Methods We considered 202 consecutive Italian PCOS nondiabetic patients and 101 age-matched controls. PCOS was diagnosed applying the Rotterdam diagnostic criteria. Steatosis was diagnosed if hepatic steatosis index (HSI) >36, while fibrosis by using the FIB-4 score. As surrogate estimate of insulin sensitivity we considered the insulin sensitivity index (ISI). Free an…

0301 basic medicineSteatosisendocrine system diseasesPhysiologylcsh:MedicinePathology and Laboratory MedicineBiochemistryBody Mass IndexCytopathology0302 clinical medicineEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseMedicine and Health SciencesInsulinlcsh:ScienceMultidisciplinaryLiver DiseasesFatty liverMiddle AgedPolycystic ovaryLipidsCholesterolOncologyPhysiological Parameters030211 gastroenterology & hepatologyFemalePolycystic Ovary SyndromeResearch ArticleAdultmedicine.medical_specialtyGastroenterology and Hepatology03 medical and health sciencesInsulin resistanceInternal medicinemedicineHumansObesityRisk factorTriglyceridesDiabetic Endocrinologybusiness.industryFree androgen indexHyperandrogenismCholesterol HDLBody Weightlcsh:RCancers and NeoplasmsBiology and Life Sciencesmedicine.diseaseFibrosisHormonesFatty Liver030104 developmental biologyEndocrinologyAnatomical Pathologylcsh:QSteatosisInsulin ResistancebusinessHyperandrogenismGynecological TumorsDevelopmental Biologyinsulin resistance PCOS
researchProduct

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the onc…

2015

abstract The fetal tight junction molecule claudin 6 (CLDN6) is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need. We engineered 6PHU3, a T-cell-engaging bispecific single chain molecule (bi-(scFv)2) with anti-CD3/anti-CLDN6 specificities, and characterized its pharmacodynamic properties. Our data show that upon engagement by 6PHU3, T cells strongly upregulate cytotoxicity and activation markers, proliferate and acquire an effector phenotype. 6PHU3 exerts potent killing of cancer cells in vitro with EC50 values in the pg/mL range. Subcutaneous xenograft tumors in NSG mice engrafted with human PBMCs are eradicat…

0301 basic medicineT cellBispecific antibodyT cell engagementImmunologyxenograft mouse model03 medical and health sciencesmedicineImmunology and AllergyClaudinCytotoxicityoncofetal tumor markerOriginal ResearchbiologyTumor-infiltrating lymphocytesT-cell engagersolid tumorsMolecular biologyIn vitro030104 developmental biologymedicine.anatomical_structureOncologyideal targettumor-infiltrating lymphocytesCancer cellbiology.proteintargeted immunotherapyAntibodyCD8Oncoimmunology
researchProduct

Exosome-mediated drug resistance in cancer: the near future is here.

2016

Drug resistance exerts a crucial role in several cancer treatments. Understanding the resistance mechanisms against different therapeutic agents can be helpful to determine the prognosis, but remains a tricky task. In this context, tumor-derived exosomes (TDEs) may give crucial answers about these resistance mechanisms. Exosomes are biological nanovesicles with an average size around 30–100 nm of diameter (Figure 1) that originate from the endocytic pathway by the inward budding of multivesicular bodies (MVB), and they function as cell-free messengers, involved in the cell–cell communication [Kowal et al. 2014]. It has been demonstrated that both cells in physiological and pathological cond…

0301 basic medicineTumor microenvironmentAngiogenesisEndocytic cycleContext (language use)Drug resistanceBiologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282ExosomeMicrovesiclesCell biology03 medical and health sciencesEditorial030104 developmental biology0302 clinical medicineExosomes cancer drug resistanceOncologySettore BIO/13 - Biologia Applicata030220 oncology & carcinogenesismicroRNAImmunologyHuman medicine
researchProduct

Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma

2017

Antonio Miguel,1 Luis Sendra,1 Verónica Noé,2 Carles J Ciudad,2 Francisco Dasí,3,4 David Hervas,5 María José Herrero,1,6 Salvador F Aliño17 1Department of Pharmacology, Faculty of Medicine, University of Valencia, 2Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Barcelona, 3Research University Hospital of Valencia, INCLIVA Health Research Institute, 4Department of Physiology, Faculty of Medicine, University of Valencia Foundation, 5Biostatistics Unit, 6Pharmacogenetics Unit, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 7Clinical Pharmacology Unit, ACM Hospital Univers…

0301 basic medicineantisense oligonucleotidemedicine.medical_treatmentCellImmunoteràpiaIpilimumabchemical and pharmacologic phenomenaImmunotheraphyVacuneslcsh:RC254-282OncoTargets and Therapy03 medical and health sciencesgene silencingCancer immunotherapymedicineGene silencingPharmacology (medical)IL-2 receptorCàncerOriginal ResearchTumorsCancerVaccinescancer immunotherapybiologybusiness.industryFOXP3hemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensVaccinationTreg030104 developmental biologymedicine.anatomical_structureantitumor vaccineOncologybiology.proteinCancer researchAntibodybusinessmedicine.drugOncoTargets and Therapy
researchProduct

Γδ T Cell-Based Immunotherapy in Melanoma: State of the Art

2019

Metastatic melanoma is still associated with a poor prognosis, and there is increasing interest in immunotherapy alone or in combination with other adjuvant therapies. Γδ T lymphocytes play a pivot role in the immune response against cancer, but while γδ-based immunotherapy is already a clinical reality for several solid tumors, data on melanoma are still limited and fragmented. This systematic review presents preclinical and clinical evidence for a role of γδ T lymphocytes in immunotherapeutic strategies for advanced melanoma and discusses research state of the art and future perspectives. Current strategies focus on in vivo stimulation, and ex vivo adoptive therapy and vaccination; result…

0301 basic medicinebusiness.industrymedicine.medical_treatmentMelanomaT cellCancerReview ArticleImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-28203 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemmedicine.anatomical_structureOncologyAntigen030220 oncology & carcinogenesismedicineCancer researchbusinessT-Lymphocytes | Receptors Antigen T-Cell gamma-delta | Cell subsetsAdjuvantEx vivoJournal of Oncology
researchProduct